Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I3OS
|
|||
| Former ID |
DIB005432
|
|||
| Drug Name |
Rebmab-100
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Fallopian tube cancer [ICD-11: 2C74; ICD-10: C57.0] | Phase 2 | [1] | |
| Company |
Genesis Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Galactoside 3(4)-L-fucosyltransferase (FUT3) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027929) | |||
| REF 2 | A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecol Oncol. 2015 Aug;138(2):272-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.